Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ruxolitinib & Myelofibrosis / Primary myelofibrosis, Ruxolitinib is approved by both the FDA and EMA for Myelofibrosis / Primary myelofibrosis (1, 3).
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib showed the Kaplan–Meier estimate of median survival from ruxolitinib initiation was 44.4 months (95% CI, 38.8–50.2 months). Approximately one-quarter (23%) of patients continued ruxolitinib after progression (2).
Ruxolitini…